MedTrace Logo

A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs

NCT02510781 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2015-07-29

No results posted yet for this study

Summary

Docetaxel plus carboplatin and trastuzumab has been a standard treatment for patients with human epidermal growth factor receptor-2（HER-2）positive. The investigators witnessed a higher pathological complete remission(pCR) rate but no obvious increase in cardiac toxicity when used the anthracycline instead of carboplatin. The investigators expect to carry out a large sample size clinical research to optimize the existing therapeutic regimen

Conditions

  • Breast Neoplasms

Interventions

DRUG

Epirubicin

75mg/m2 d1 evry 21days

DRUG

Docetaxel

75mg/m2 d1 evry 21days

DRUG

Trastuzumab

6mg/kg(loading dosage is 8mg/kg)

DRUG

Carboplatin

Area Under Curve(AUC)=6 d1 evry 21days

Sponsors & Collaborators

  • Hospital Affiliated to Military Medical Science, Beijing

    lead OTHER

Principal Investigators

  • zefei jiang, Ph.D · Academy MMS,China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
69 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-12-31
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02510781 on ClinicalTrials.gov